Skip to main content

Search articles in News

Found 2,761 articles

  • IQVIA Named a Leader in Medical Affairs and Regula

    IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group

    • 12 Jul 2024
    • Editor

    IQVIA™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness.

  • What Does a Bioinformatician Do?

    What Does a Bioinformatician Do?

    • 11 Jul 2024
    • Lucy Walters

    Bioinformatics is an interdisciplinary field that integrates computer science, mathematics, statistics, and biology to manage and analyse biological data. This field is crucial to the life sciences industry for its role in understanding complex biological processes, leading to significant advances in drug discovery, genetic research, and personalised medicine.

  • London-based AI platform celebrated at prestigious

    London-based AI platform celebrated at prestigious technologies competition

    • 11 Jul 2024
    • Editor

    A London-based AI-driven pharmaceutical company, Ignota Labs, that could transform the world around us has been named a winner of the Royal Society of Chemistry’s 2024 Emerging Technologies Competition.

  • Pfizer to Launch Process to Identify a Successor f

    Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development

    • 11 Jul 2024
    • Editor

    Pfizer Inc. (NYSE: PFE) today announced that the company is launching the process to identify a successor for Dr. Mikael Dolsten, Pfizer’s Chief Scientific Officer and President, Pfizer Research & Development, who will depart the company after a more than 15-year stellar career.

  • ICON recognised for leadership position in clinica

    ICON recognised for leadership position in clinical research industry and as socially responsible employer

    • 11 Jul 2024
    • Editor

    ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addition to its efforts in inclusion, sustainability and as an employer of choice.

  • AbbVie Announces Appointment of Roopal Thakkar, M.

    AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer

    • 11 Jul 2024
    • Editor

    AbbVie (NYSE:ABBV) today announced that Roopal Thakkar, M.D. who currently serves as senior vice president, chief medical officer, global therapeutics has been appointed to the position of executive vice president, research & development and chief scientific officer. In this position, Dr. Thakkar will lead the company's global R&D organization of more than 14,000 team members across all phases of discovery and development, including therapeutics and aesthetics.

  • Cambridge Cognition secures Innovate UK grant to c

    Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project

    • 11 Jul 2024
    • Editor

    Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.

  • Jazz Pharmaceuticals Promotes Samantha Pearce to C

    Jazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer

    • 10 Jul 2024
    • Editor

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Samantha Pearce, Senior Vice President (SVP), Europe and International, has been promoted to Chief Commercial Officer (CCO) effective August 1, 2024.

  • Evotec and Pfizer collaborate to advance drug disc

    Evotec and Pfizer collaborate to advance drug discovery in France

    • 10 Jul 2024
    • Editor

    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced it has entered into a multi-year master research collaboration and option and license agreement with Pfizer. Under the agreement, Evotec and Pfizer will initially focus on early discovery research for metabolic and infectious diseases.

  • Curve Therapeutics strengthens Leadership Team wit

    Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones

    • 9 Jul 2024
    • Editor

    Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Simon Jones as Chief Financial Officer (CFO) and Chief Operating Officer (COO).

  • Allucent Awarded 5-Year BARDA Agreement Aimed at E

    Allucent Awarded 5-Year BARDA Agreement Aimed at Enhancing and Accelerating Decentralized Clinical Trials for Medical Countermeasure Development

    • 9 Jul 2024
    • Editor

    Allucent, a global mid-sized clinical research organization (CRO), announced today that it has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for its new Decentralized Clinical Operations for Healthcare and Research (D-COHRe) initiative.

  • Roche receives CE Mark for its AI-enabled continuo

    Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

    • 9 Jul 2024
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received the CE Mark for its Accu-Chek SmartGuide® continuous glucose monitoring (CGM) solution. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy.

  • Lilly to Acquire Morphic to Improve Outcomes for P

    Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

    • 9 Jul 2024
    • Editor

    Eli Lilly and Company (NYSE: LLY) and Morphic Holding, Inc. (NASDAQ: MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases.

  • Boehringer Ingelheim produces its own green energy

    Boehringer Ingelheim produces its own green energy

    • 9 Jul 2024
    • Editor

    Boehringer Ingelheim inaugurated a biomass power plant at its Ingelheim site on Monday. With the new power plant, Boehringer Ingelheim is optimizing its energy supply and protecting the environment at the same time: Around 50,000 tons of CO2 are saved per year.

  • Just – Evotec Biologics expands tech partnership f

    Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz

    • 9 Jul 2024
    • Editor

    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX , ISIN: DE0005664809; NASDAQ: EVO) today announced that its biologics segment, Just – Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz.

  • CNX Therapeutics Announces CFO Transition: Olga Lu

    CNX Therapeutics Announces CFO Transition: Olga Lund to depart, Claire Masterson Joins as new CFO

    • 4 Jul 2024

    CNX Therapeutics Limited (“CNX Therapeutics”), a speciality pharmaceutical company with a focus on improving access to essential medicines, today announced that Olga Lund will be stepping down from her role as Chief Financial Officer to take a career break and spend more time with her family. Claire Masterson, an experienced financial executive, will succeed Ms. Lund as CFO, effective July 1, 2024.

  • Anacura acquires OHMX.bio, adding multi-omics for

    Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services.

    • 4 Jul 2024
    • PharmiWeb Editor

    Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology.

  • Sipavibart EMA regulatory submission accepted unde

    Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

    • 3 Jul 2024
    • Pharmiweb Editor

    AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.

  • Agreement to explore Optimer vehicles for targeted

    Agreement to explore Optimer vehicles for targeted delivery of siRNA

    • 3 Jul 2024
    • PharmiWeb Editor

    New collaboration will evaluate Aptamer’s fibrotic liver delivery vehicles with siRNA

  • BC Platforms Announces Appointment of New Chairman

    BC Platforms Announces Appointment of New Chairman, Alex Dickinson

    • 3 Jul 2024
    • PharmiWeb Editor

    BC Platforms, a global leader in real world data, healthcare data management, and analytics, today announces the appointment of a new Chairman of the Board.